Celator Pharma: CPX-351 Outperforms Control Arm In Overall Response Rate

(RTTNews) - Celator Pharmaceuticals Inc. (CPXX) announced final induction response rate results in the Phase 3 study comparing CPX-351 liposome injection to the standard of care regimen, referred to as 7+3 (conventional cytarabine and daunorubicin treatment), in patients with untreated high-risk (secondary) acute myeloid leukemia. The company said the results showed that CPX-351 produced a relative improvement in induction response rate of 43.2%. The company said the data validate the induction response rates observed in the Phase 2 study.

Induction response rate is a key secondary endpoint in the study. The company said, data on the primary endpoint of the study, overall survival, are expected in the first quarter of 2016.